Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | MMP2 | P08253 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17526270 | 0.80 | CA2 (0.66) | KMT2AMEN1CA2MMP2CA12 | |
| SCHEMBL5878505 | 0.78 | CA2 (0.67) | KMT2AMEN1CA2MMP2CA12 | |
| SCHEMBL922441 | 0.77 | KMT2A (0.77) | KMT2AMEN1CA2MMP2CA1 | |
| SCHEMBL6468938 | 0.76 | KMT2A (0.58) | KMT2AMEN1CA2MMP2CA12 | |
| SCHEMBL11881609 | 0.75 | KMT2A (0.64) | KMT2AMEN1CA2MMP2CA12 | |
| SCHEMBL922350 | 0.75 | CA2 (0.71) | KMT2AMEN1CA2MMP2CA12 | |
| SCHEMBL13590904 | 0.75 | CA2 (0.75) | KMT2AMEN1CA2MMP2CA12 | |
| SCHEMBL5188248 | 0.75 | CA2 (0.65) | KMT2AMEN1CA2MMP2CA12 | |
| SCHEMBL6024959 | 0.75 | KMT2A (0.77) | KMT2AMEN1CA2MMP2CA12 | |
| Dinsed SCHEMBL1814194 | 0.74 | KMT2A (1.00) | KMT2AMEN1CA2MMP2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244648-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORP (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-7022717-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-04-04 | — | — | US | disclosed |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | BRIDGER GARY J | 2006-03-30 | — | — | US | disclosed |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2004-05-27 | — | — | US | disclosed |
| US-6667320-B2 | For therapy of infalmmation; asthma, cancer, arthritis, multiple sclerosis; prophylaxis of infection of target cells by a human immunodeficiency virus (HIV) | ANORMED (CA) | 2003-12-23 | — | — | US | disclosed |
| EP-1244648-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2002-06-20 | — | — | US | disclosed |
| WO-2001044229-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | KMT2A 2209/4885MEN1 3670/4885CA2 4609/4885 |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | KMT2A 2209/4885MEN1 3670/4885CA2 4609/4885 |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | KMT2A 2209/4885MEN1 3670/4885CA2 4609/4885 |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | KMT2A 2209/4885MEN1 3670/4885CA2 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.